Jeil Pharmaceutical Holds Launch Symposium for Overactive Bladder Treatment 'Beoba Tablets'

[Asia Economy Reporter Myunghwan Lee] Jeil Pharmaceutical announced on the 3rd that it successfully held a symposium for the launch of a new drug for overactive bladder treatment with a new ingredient, 'Beoba Tablet 50mg,' at the Grand Intercontinental Seoul Parnas Hotel on the 1st.

The symposium consisted of an introduction to Beoba Tablet, the current status of major global clinical trials, bridging clinical results, differences from existing β3-adrenergic receptor agonists, and a Q&A session.

Beoba Tablet is a β3-adrenergic receptor agonist with a new ingredient that selectively acts on sympathetic nervous system receptors to relax the bladder detrusor muscle, helping to treat symptoms such as frequent urination, urgency, and urge urinary incontinence. Until now, the only β3-adrenergic receptor agonist on the market was the single ingredient mirabegron, but Beoba Tablet containing the ingredient vibegron was launched in January.

Vibegron is known to have over 9,000 times higher selectivity for β3 receptors compared to β1 and β2 receptors. Additionally, vibegron’s maximum response rate for β3 receptors is 99.2%. This is higher than the 80.4% response rate of mirabegron, another β3 agonist, and it has the advantage of lower stimulation of β1 and β2 receptors, reducing the risk of cardiovascular side effects. Jeil Pharmaceutical also emphasized that there is very little concern about interactions with drugs metabolized via the CYP2D6 pathway, and that it can be administered at standard doses to patients with liver or kidney impairment.

Professor Kyuseong Lee of the Department of Urology at Samsung Seoul Hospital, who chaired the symposium, said, "Beoba Tablet is a new ingredient drug introduced domestically that is expected to provide high-quality treatment effects for Korean patients with overactive bladder due to its excellent symptom improvement and low incidence of adverse reactions."

Won Hyerim, Beoba Tablet PM at Jeil Pharmaceutical, said, "Beoba Tablet containing vibegron offers high treatment efficacy for patients with overactive bladder and has fewer side effects such as constipation or dry mouth. We plan to make efforts to help more patients through rapid supply."

Jeil Pharmaceutical plans to hold additional Beoba launch symposiums in various regions, including Busan, within the first half of the year, starting with this Seoul symposium.